Disclosed herein are compounds of Formula I′:; ;or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a patient with one or more of the above ...
I enjoyed speaking with you and learning about HP patent transaction program 它是非常好谈话与您在电话这个过去星期。 我喜欢讲与您和得知HP专利处理程序 [translate] aEXECUTION DRAWINGS FOR PRESSURISING: CIRCUIT DIAGRAMS 施行图画为加压: 电路图 [translate] aDo you have an Amazon.com password 您有一...
Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IlIa, lIIb, IlIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the...
A chemical compound shown in formula (I) below and an isomer thereof or a pharmaceutically acceptable salt thereof. The compound improves THR-β agonistic activity while also improving selectivity for THR-α, thereby improving pharmaceutical quality.YU, SHANGHAILI, BEN...
How to treat liver injury or lipid disorder with thr beta agonistsProblem to be solved: to provide a method and a compound for treating liver injury or lipid disorder.The first periodAdministering the first dose of 2 - (3,5-dichloro-4 - (5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl) ...
The subject of the invention is the new beta crystalline form of 4,4'-diamino-3,3'-dibromo-dianthraquinonyle-1,1 'having the characteristic lines of the X-ray diffraction spectrum (determined according to the Guinier method / De Wolff, using the Cu Kalpha1) radiation shown in Figure 1,...
T cell receptor Vbeta-Dbeta-Jbeta sequence LGRAGLTY (Leu Gly Arg Ala Gly Leu Thr Tyr) and methods for its detection and uses in treating autoimmune diseasesDisclosed is a controlled release dosage form suitable for administration to a subject comprising 5,8,14-triazatetra-cyclo[10.3.1.02,...
0,02 mg etinylostradiol (som betadexclathrat) og 3mg drospirenonFIELD: medicine, endocrinology, pharmacy.SUBSTANCE: invention relates to a pharmaceutical composition comprising drospirenone as the first active agent in the amount corresponding to daily dose from 2 to 4 mg in administration of ...